$Crown Electrokinetics(CRKN.US$ about to hit 2.6 before picking up steam. shaking panic sellers
1
2
joeyboulevard
commented on
$ZyVersa Therapeutics(ZVSA.US$
ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
ZyVersa Therapeutics (ZVSA) announces publication of research demonstrating that its Inflammasome ASC Inhibitor IC 100 restored retinal structure and function in a Retinopathy of Prematurity (ROP) animal model.
The study, published in Angiogenesis, showed that IC 100 suppressed ret...
ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
ZyVersa Therapeutics (ZVSA) announces publication of research demonstrating that its Inflammasome ASC Inhibitor IC 100 restored retinal structure and function in a Retinopathy of Prematurity (ROP) animal model.
The study, published in Angiogenesis, showed that IC 100 suppressed ret...
8
joeyboulevard
commented on
![Picture](https://ussnsimg.moomoo.com/sns_client_feed/70719271/20240725/1721843826614-random3648-70719271-android-org.jpeg/thumb?area=100&is_public=true)
1
2
joeyboulevard
commented on
$Anixa Biosciences(ANIX.US$ EXCLUSIVE: Anixa Biosciences Tells Benzinga Co. Announces FDA Approval Of Individual Patient IND For Its Ovarian Cancer CAR-T Therapy
4
9
joeyboulevard
liked
$BioAtla(BCAB.US$ Reuters· just
Bioatla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (Cab-Ror2-ADC) for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Bioatla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (Cab-Ror2-ADC) for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
2
joeyboulevard
commented on
1
8